Medolife, a majority-owned subsidiary of Quanta Inc (OTCMKTS:QNTA) announced yesterday pre-clinical study results conducted at one of the leading cancer research centers in the United States showing that the Company’s lead drug candidate Escozine® caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells.
Such a result is significant not only to the Quanta Inc (QNTA) ongoing clinical research, but could have tremendous effects on cancer treatments,
“These results not only met our expectations, but exceeded them,” said Medolife CEO Dr. Arthur Mikaelian. “ While we knew that Escozine had cancer fighting therapeutic benefits, to see over 95 percent of cancer cells killed when introduced to the drug was truly groundbreaking. Cancer is one of the leading causes of death worldwide and finding an effective therapeutic is known as the holy grail of medicine. While we still have research to conduct in order to prove this drug is an effective treatment for cancer, results like these from such a credible institution will pave the way for this further exploration.”
It is a significant development for Medolife and marks a major milestone for the company as it continues to develop the product. It goes without saying that investors may want to keep an eye on Quanta Inc (OTCMKTS:QNTA).
 Groundbreaking Results In Escozine® Testing){kind=link}